IMPORTANT MRNA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Moderna, Inc. securities between January 18, 2023, and June 25, 2024, of the upcoming lead plaintiff deadline on October 8, 2024, for a class action lawsuit related to misleading statements about the effectiveness of their RSV vaccine [2][5]. Group 1: Class Action Details - Investors who bought Moderna securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 8, 2024 [3]. - The lawsuit alleges that Moderna made false and misleading statements regarding the effectiveness of its mRNA-1345 RSV vaccine, which was claimed to be less effective than represented [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4].